Dementia Linked With Treatment For Chronic Lower Back Pain
A team from Case Western Reserve University School of Medicine, Arizona State University, and the MetroHealth Medical Center in the US crunched the numbers on 26,416 records of patients with chronic lower back pain, looking at the relationship between prescriptions for the anticonvulsant gabapentin and dementia diagnoses.
Having six or more gabapentin prescriptions was linked to a significant increase in dementia risk and mild cognitive impairment (MCI), the data showed: those in that group were 29 percent and 85 percent more likely to be diagnosed with dementia and MCI respectively, within 10 years.
Related: Massive Study Links 15 Factors to Early Dementia Risk
The increase was higher among patients aged between 35 and 49, and also rose with the number of prescriptions given, the researchers found. Though the study can't establish a cause for the increase, physicians are encouraged to keep a close eye on patients taking the drug.
"Gabapentin prescription in adults with chronic low back pain is associated with increased risk of dementia and cognitive impairment, particularly in non-elderly adults," write the researchers in their published paper.
"Physicians should monitor cognitive outcomes in patients prescribed gabapentin."
Sold under brand names including Neurontin, gabapentin has proved to be less addictive than opioids, making it more likely to be prescribed in recent years. The drug does have some known side effects though, including extreme moods and allergic reactions.
This isn't the first time researchers have examined associations between gabapentin and dementia, but previous studies haven't agreed on whether or not concerns are warranted.
One of the study's strengths is the relatively large sample size of its participants, though the sample largely consisted of just one group of people – those with chronic lower back pain. A study published in 1997 found no link between gabapentin and cognitive decline in people with epilepsy, so it's important to continue to widen the data set.
These conflicting results could suggest unique mechanisms among patients with the type of backpain that leads to a gabapentin prescription that also increases their risk of dementia, like a certain type of location of inflammation.
But gabapentin works by dampening some of the brain's key communication channels, in order to provide relief from pain or make seizures less likely. So the worry is that it could also be damaging links between neurons in ways that might lead to dementia – a concern backed up by this latest study.
Dementia is a challenging condition to study with so many potential factors to account for, but each study gets us closer to the full picture of how the brain breaks down over time.
"We hope the current study promotes further research to delineate whether gabapentin plays a causal role in the development of dementia and the underlying mechanisms of this relationship," write the researchers.
The research has been published in Regional Anesthesia & Pain Medicine.
Related News
8 Babies Born in UK Using Radical 'Three Parent' IVF Technique
These 4 Simple Exercises Could Help Break Your Insomnia
Energy Drinks Seen Fuelling Cancer, But There's a Strange Catch
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Measles, rubella and polio: The return of preventable diseases
With outbreaks of previously eradicated measles leading the news for months, more epidemics may be in store for the U.S. As vaccination rates among children continue to plummet, concerns are rising over the potential for infectious diseases to spread rampantly in the coming years and decades. Research published in the medical journal JAMA suggests a continued decline could lead to millions of infections from diseases currently considered under control or eradicated. Measles: Worst year in decades; Schumer responds The impact of declining vaccination rates is already becoming more visible. As of the middle of 2025, the U.S. is having the worst year for measles in over three decades. The Centers for Disease Control and Prevention (CDC) have reported 1,288 confirmed cases in 38 states as of July 8. Senate Minority Leader Chuck Schumer (D-N.Y.) recently sent a letter to Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. asking him to declare a health emergency over the latest measles outbreaks. Schumer blamed the administration for the worst measles outbreak in 33 years, citing cuts to disease experts, halted grants and politicized vaccine policy. 'To prevent this historic record high spread from reaching further and to save lives, you shouldimmediately declare a Public Health Emergency for measles,' Schumer said. If vaccination rates continue at the same pace, researchers predict 851,300 cases of measles over the next 25 years. Additionally, if rates were to fall by even 10 percent cases would shoot up to 11.1 million over the next 25 years. Rubella: Pregnant women at risk Rubella, or 'German measles,' is another previously eradicated disease in the U.S. that could see heightened levels of infection if vaccination rates remain the same. According to the World Health Organization, before the introduction of the vaccine, up to 4 babies in every 1,000 births were born with rubella. The condition remains the leading cause of vaccine-preventable birth defects worldwide. Pregnant women are unable to get the vaccine because it contains the live virus. So, as community immunity weakens, the risk of rubella resurging grows, placing unborn children and expectant mothers in preventable danger. Polio could return Polio, a disease that once paralyzed and killed thousands of children across the U.S., could also reemerge if vaccination rates continue to fall. Though declared eliminated in the country in 1979, the virus still exists in parts of the world and can be reintroduced through international travel. With polio vaccination rates declining in 30 states, the risk of outbreaks grows, potentially leading to thousands of cases in the coming decades. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
U.S. health insurers seek largest jump in Obamacare premiums since 2018, study shows
By Christy Santhosh (Reuters) -U.S. insurers are requesting the biggest premium increases for Obamacare plans since 2018, according to an analysis by health-research firm KFF, prompted by the looming expiry of premium tax credits and potential tariffs on medical goods. Insurers are proposing a median premium increase of 15% for 2026, KFF said, citing data from rate filings of 105 insurers across 19 states. In recent years, premiums in the plans have been relatively flat or grown only modestly. The industry has been struggling with changing enrollment patterns and rising medical costs. Insurers such as UnitedHealth and Centene have suspended their annual earnings forecasts while others have lowered their profit targets. Insurance companies pointed to the slower market growth and a rise in higher-risk patients enrolled in plans under Affordable Care Act, or Obamacare. The plans primarily serve people who do not get insurance either through an employer, Medicaid for low-income people or Medicare for older adults. The companies also cited the planned 2026 expiration of COVID-era premium tax credits as a reason, with KFF's analysis showing insurers will raise premiums by an additional 4% than they would if the enhanced tax credits were renewed. For 2026, insurers generally reported that the underlying cost of healthcare remains around last year's 8% increase. Several noted that GLP-1 weight-loss and diabetes drugs are driving costs higher, along with labor market pressures affecting negotiations with healthcare providers. Insurers also flagged uncertainty surrounding the "ACA Integrity Rule", a set of regulations finalized to strengthen verification and reduce improper enrollments in Obamacare plans, according to the report. Health insurers Centene, Molina, UnitedHealth, Cigna, Elevance, CVS Health, Oscar Health and Kaiser Permanente did not immediately respond to requests for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
2 hours ago
- Medscape
GLP-1 RAs Protective Against Stroke, Neurodegeneration?
TOPLINE: Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), particularly semaglutide and tirzepatide, was associated with a 37% reduced risk for dementia and a 19% reduced risk for ischemic stroke in adults with type 2 diabetes (T2D) and obesity compared to the use of other antidiabetic drugs in a new retrospective cohort study. The neuroprotective effects of GLP-1 RAs were more pronounced in older adults, women, and those with a BMI of 30-40. METHODOLOGY: Investigators analyzed data on more than 60,000 adults aged 40 years or older with T2D and obesity and without type 1 diabetes or preexisting neurodegenerative or cerebrovascular diseases, obtained from electronic health records between 2017 and 2024. After propensity-score matching, participants receiving semaglutide or tirzepatide were assigned to the GLP-1 RA group (n = 30,430; mean age, 58 years; 50% women; 56% White individuals), and those receiving biguanides, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 inhibitors, and SGLT2 inhibitors were assigned to the 'other antidiabetic drug' group (n = 30,430; mean age, 58 years; 51% women; 56% White individuals). Primary outcomes were the incidence of new‐onset neurodegenerative diseases (dementia, Parkinson's disease, and mild cognitive impairment) and cerebrovascular diseases (ischemic stroke and intracerebral hemorrhage). The secondary outcome was all-cause mortality. TAKEAWAY: Patients taking GLP-1 RAs had a significantly lower risk for dementia (hazard ratio [HR], 0.63), ischemic stroke (HR, 0.81), and all-cause mortality (HR, 0.70) than those taking other antidiabetic drugs. Compared with use of other antidiabetic drugs, use of semaglutide was associated with reduced risk for dementia (HR, 0.63), whereas use of tirzepatide was associated with reduced risk for stroke (HR, 0.69) and all-cause mortality (HR, 0.48). No significant differences in risk for Parkinson's disease or intracerebral hemorrhage were observed between the GLP-1 RA group and the other antidiabetic group. The neuroprotective effects of GLP-1 RAs were more pronounced in women (HR, 0.85), adults aged 60 years or older (HR, 0.85), White individuals (HR, 0.86), and those with a BMI of 30-40 (HR, 0.82). IN PRACTICE: 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with T2D and obesity,' the investigators wrote. 'If shown to be protective for neurodegenerative diseases in future trials, GLP-1 RAs could potentially be used clinically in disease prevention in the future,' Sarah Marzi, PhD, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, said in an online comment. Marzi was not involved with the current research. SOURCE: The study was led by Huan-Tang Lin, MD, PhD, Chang Gung Memorial Hospital, Taoyuan, Taiwan. It was published online on July 15 in JAMA Network Open. LIMITATIONS: As an observational study, residual confounding from unmeasured factors such as frailty or functional status could not be excluded, potentially introducing healthy user or selection bias. The database used lacked biomarker data, genetic profiles, and neuroimaging assessments, limiting further mechanistic interpretations. The analysis did not account for death as a competing risk. Additionally, medication exposure was inferred from prescriptions without confirmation of actual adherence or accurate drug doses. DISCLOSURES: The study was funded by the Ministry of Science and Technology, Taiwan, and the Chang Gung Memorial Hospital. The investigators reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
